Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2017 05/23/2017 05/24/2017 05/25/2017 05/26/2017 Date
10.65(c) 10.5(c) 10.525(c) 10.5(c) 10.25(c) Last
442 252 439 271 826 293 658 538 324 891 Volume
+0.95% -1.41% +0.24% -0.24% -2.38% Change
More quotes
Financials ($)
Sales 2017 234 M
EBIT 2017 104 M
Net income 2017 35,2 M
Debt 2017 243 M
Yield 2017 -
Sales 2018 243 M
EBIT 2018 109 M
Net income 2018 52,3 M
Debt 2018 141 M
Yield 2018 -
P/E ratio 2017 15,95
P/E ratio 2018 10,96
EV / Sales2017 3,08x
EV / Sales2018 2,54x
Capitalization 476 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs.It focuses on gastroenterology, ophthalmology, and oncology-related disorders.The company's product pipeline includes AMITIZA for... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
05/22 SUCAMPO PHARMACEUTICALS : Financial Statements and Exhibits (form 8-K/A)
05/22 SUCAMPO PHARMACEUTICALS : Technical Reports on Drug Makers Stocks -- Synergy Pha..
05/15 SUCAMPO PHARMACEUTICALS : Cerecor Appoints Steven Boyd and Peter Greenleaf to Bo..
05/12 SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the Bank of A..
05/11 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of ..
05/03 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
05/03 SUCAMPO PHARMACEUTICALS, INC. : Investor Network: Sucampo Pharmaceuticals, Inc. ..
05/03 SUCAMPO PHARMACEUTICALS : tops 1Q revenue forecasts
05/03 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Results of Operations ..
05/03 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
Latest Tweets
05/2510 lesser-known facts about Joshua Wong that the Netflix film brings into foc.. 
05/24AlphaMark Advisors LLC Buys Shares of 78,500 Sucampo Pharmaceuticals, Inc. $S.. 
05/23Sucampo Pharmaceuticals (SCMP) Presents At Bank of America Merrill Lynch 2017.. 
05/22Positive Media Coverage Unlikely to Affect Sucampo Pharmaceuticals $SCMP Stoc.. 
05/18Want automatic email alerts for $GRH $SCMP $SSP $TCPI $SCON? Subscribe to Mar.. 
More tweets
Qtime:18
News from SeekingAlpha
05/23 Sucampo Pharmaceuticals (SCMP) Presents At Bank of America Merrill Lynch 2017..
05/03 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q1 2017 Results - Earn..
05/03 Sucampo Pharmaceuticals, Inc. 2017 Q1 - Results - Earnings Call Slides
05/03 Sucampo Pharma Q1 revenues up 19%; updates guidance
05/03 Sucampo misses by $0.04, beats on revenue
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends SUCAMPO PHARMACEU...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 18,1 $
Spread / Average Target 76%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Matthew Maxwell Donley EVP-Human Resources & Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICAL..-22.51%476
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.86%91 185
GILEAD SCIENCES, INC.-9.93%84 284
REGENERON PHARMACEUTIC..24.14%48 380
ACTELION LTD26.30%30 602
More Results